Table 1.
Blood glucose level of treated and non-treated alloxan-induced diabetic rats
| Treatment /day | Day 0 (mg/dL) | Day 7 (mg/dL) | Day 14 (mg/dL) | Day 21 (mg/dL) |
|---|---|---|---|---|
| N.C. | 117.0 (7.7) | 117.8 (11.3) | 116.4 (11.6) | 117.6 (9.8) |
| P. C. (DI alone) | 421.4 (55.1)a | 414.6 (45.7)a | 404.0 (82.0)a | 413.0 (88.1)a |
| DI + 20 g/L P.a. | 441.4 (61.4) | 239.2 (46.4)b (↓ 45.8%) | 221.4 (45.3)b (↓ 49.8%) | 216.6 (42.4)b (↓ 50.9%) |
| DI + 30 g/L P.a. | 436.8 (50.8) | 215.6 (25.3)b (↓ 50.6%) | 195.2 (12.3)b (↓ 55.3%) | 192.0 (19.0)b (↓ 56.0%) |
| DI + 40 g/L P.a. | 460.2 (83.8) | 210.6 (15.8)b (↓ 54.2%) | 192.8 (15.5)b (↓ 58.1%) | 189.0 (11.4)b (↓ 58.9%) |
| DI + GBM | 448.2 (54.9) | 186.2 (8.9)b (↓ 58.5%) | 184.2 (14.9)b (↓ 58.9%) | 187.2 (7.0)b (↓ 58.2%) |
*All values are expressed as the mean (SD) (n = 5); a P < 0.05 vs negative control group; b P < 0.05 vs. diabetic control group (NC = Negative Control; PC = Positive Control, DI = diabetic-induced, and GBM = glibenclamide. Figures in parentheses indicate a percentage increase or decrease in BGL (blood glucose level) when compared to the NC.